◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksM › MMED

MiniMed Group, Inc. Common Stock (MMED) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · DATA UPDATED 2026-09-19

MiniMed Group, Inc. Common Stock (MMED) operates in the MEDICAL INSTRUMENTS & SUPPLIES industry and is headquartered in Northridge, United States with about 8,000 employees. Its market capitalization is roughly $6 billion. In the fiscal year ended 2026-04-30, MMED reported $3.1B in revenue and ($331M) in net income.

MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes.

Interactive charts & full statements → Open the MMED valuation workbench →

MMED Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-07-312026-04-302025-04-302024-04-302023-04-30
Total Revenue$3.2B$3.1B$2.7B$2.5B$2.2B
Gross Profit$1.7B$1.7B$1.5B$1.4B$1.3B
Gross Margin %53.8%54.2%56.2%58.2%58.3%
Operating Income (EBIT)($188M)$49M($202M)($69M)($69M)
Operating Margin %-5.8%1.6%-7.4%-2.8%-3.1%
Net Income($331M)($331M)($250M)($112M)($96M)
Net Margin %-10.3%-10.7%-9.2%-4.5%-4.3%
EBITDA$49M$107M$59M$39M
Earnings Per Share (EPS)$-1.29$-0.89$-0.40$-0.34
Shares Outstanding (M)257M281M281M281M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MMED Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-07-312026-04-302026-01-312025-04-302025-01-31
Total Revenue$843M$837M$790M$724M$687M
Gross Profit$465M$480M$362M$402M$395M
Gross Margin %55.2%57.4%45.8%55.5%57.5%
Operating Income (EBIT)($2M)$82M($93M)($204M)$22M
Operating Margin %-0.2%9.8%-11.8%-28.2%3.2%
Net Income$0M($183M)($119M)($209M)($10M)
Net Margin %0.0%-21.9%-15.1%-28.9%-1.5%
EBITDA$82M($60M)
Earnings Per Share (EPS)$0.00$-0.68$-0.42$-0.74
Shares Outstanding (M)268M281M281M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MMED Free Cash Flow History

Cash flowTTM → 2026-07-312026-04-302025-04-302024-04-302023-04-30
Cash from Operations (CFO)($105M)($197M)$140M$41M($6M)
Capital Expenditures (CapEx)$211M$223M$193M$148M$167M
Free Cash Flow (FCF)($316M)($420M)($53M)($107M)($173M)
FCF Margin %-9.8%-13.5%-1.9%-4.3%-7.7%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MMED Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-07-312026-04-302026-01-312025-04-302025-01-31
Cash from Operations (CFO)($49M)($170M)$66M$83M$24M
Capital Expenditures (CapEx)$41M$56M$53M$57M$50M
Free Cash Flow (FCF)($90M)($226M)$13M$26M($26M)
FCF Margin %-10.7%-27.0%1.7%3.6%-3.8%
Dividends Paid$229M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MMED Balance Sheet History

Balance sheet2026-04-302026-04-302025-04-302024-04-30
Total Assets$4.6B$4.6B$4.2B$4.1B
Cash & Cash Equivalents$298M$298M$11M$54M
Total Liabilities$1.0B$1.0B$870M$646M
Total Debt (Short + Long-Term)$145M$145M$11M$8M
Total Shareholders' Equity$3.6B$3.6B$3.3B$3.4B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive MMED viewer.

Other Companies in MEDICAL INSTRUMENTS & SUPPLIES

← MMDAll “M” companiesMMFL →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.